The United States coffee industry is anticipating a key regulatory decision from the Food and Drug Administration (FDA) regarding the use of methylene chloride in coffee decaffeination. The agency has officially closed the public comment period on a petition seeking to ban the chemical solvent and is now deliberating on a final ruling, which could have significant consequences for the decaffeinated coffee market in the U.S.
The review was initiated by a petition filed in late 2023 by the Environmental Defense Fund (EDF) and a coalition of health and consumer groups. The petition calls for the ban based on the Delaney Clause, a provision of the Federal Food, Drug, and Cosmetic Act that prohibits food additives shown to be carcinogenic. Methylene chloride is the primary solvent used in the 'European Method,' a widespread commercial process for removing caffeine from green coffee beans. Current FDA regulations permit a residual limit of 10 parts per million (ppm) of the solvent in roasted decaf coffee.
Industry stakeholders have presented opposing views. The National Coffee Association (NCA) has strongly opposed the petition, stating that a ban would contradict scientific evidence and that the existing trace levels are safe for consumption. The association highlights that the method is crucial for supplying the approximately 10% of American adults who drink decaffeinated coffee daily. The FDA's review process included a specific request for information on the practical challenges and timelines for phasing out the solvent, indicating that regulators are considering the full scope of supply chain and manufacturing impacts a ban would entail.